GSK Archives

Expert Advice 7 Aug 2019

Why Making the Jump from Pharma to Biotech Can be a Life Changing Experience

In less than two years, Orchard Therapeutics has changed from a small, relatively unknown UK biotech specializing in gene therapy into a billion euro company listed on the Nasdaq. This is in no small part due to the skills and experience of Mark Rothera, its CEO and President, who joined the company in 2017. Orchard […]

August 7, 2019 - 13 minutesmins - By Helen Albert

News and Trends 3 Jul 2019

EU Approves Two-Drug Pill as First-Line Treatment for HIV

The two-drug pill Dovato, developed by the UK company ViiV Healthcare, has been approved as a first-line treatment for HIV, potentially causing fewer long-term side effects than current three-drug antiretroviral regimens. HIV patients currently need to take three or more antiretroviral drugs per day to keep the infection at bay. As they get older, these […]

July 3, 2019 - 2 minutesmins - By Jonathan Smith

GSK ViiV Healthcare Double HIV Treatment

News and Trends 4 Apr 2019

Update: Two-Drug HIV Treatment Effective for up to Three Years

Update (04/04/2019): ViiV Healthcare’s two-drug HIV treatment, Juluca, has successfully suppressed the HIV virus for up to three years in patients’ blood. In a clinical study, 513 HIV-infected people switched to daily pills of Juluca from their standard drug regimes, which included three or four different drugs. Juluca was effective at suppressing the virus for […]

April 4, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

Sitryx immunometabolism cancer inflammation

News and Trends 8 Oct 2018

Oxford Biotech Launches with €26M to Target ‘Immunometabolism’

Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […]

October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 3 Sep 2018

Moving from Big Pharma to Biotech – Insights from Two Biotech CEOs

According to John LaMattina in Forbes last year, more and more senior scientific executives are moving from pharma to small biotechs or startup initiatives. While the jury is out on whether this observation reflects a real trend or not, we at Labiotech are keen to learn about what drives people to make such a move! […]

September 3, 2018 - 11 minutesmins - By External Contributor

News and Trends 8 Feb 2018

GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment

ViiV Healthcare has just started a clinical trial to test if its two-drug regimen for HIV can work as well as current three-drug HIV treatment. Most antiretroviral treatments used to keep HIV at bay employ a combination of three different drugs, exposing patients to the long-term toxicity of three different compounds at once. London-based ViiV […]

February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Oct 2017

Update: GSK’s Shingles Vaccines Impresses FDA Panel who Push for its Approval

Update (24/10/2017): Shingrix has been approved by the FDA and will cost $280 (€238) for the required two shots, which should be covered by most insurance plans. Originally published on 13/9/2017 An FDA panel voted 11-0 to support the approval of GSK’s new shingles vaccine based on “impressive” efficacy and safety results in a Phase III […]

October 24, 2017 - 3 minutesmins - By Alex Dale

News and Trends 20 Sep 2017

Once-a-Day Inhaler Approved for Treatment of Deadly Lung Disease in the US

A British-American collaboration’s once-daily triple therapy inhaler has been approved for use by appropriate COPD patients in the US. A new triple therapy inhaler for chronic obstructive pulmonary disease (COPD), Trelegy Ellipta, has been developed by British giant GSK in collaboration with Innoviva in the US. The inhaler is targeted at patients who are struggling with airflow […]

September 20, 2017 - 2 minutesmins - By Alex Dale

Infographics 13 Sep 2017

The 10 Most Innovative HIV Treatments to Defeat AIDS

This infographic gathers 10 of the best HIV treatments in Europe’s pipeline that will help doctors worldwide fight against AIDS better than ever before. With an estimated 36.7 million people living with HIV worldwide, the search for an effective treatment that can overcome the fast evolution of the virus is rapidly gaining traction. In Europe, […]

September 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 3 Jul 2017

Scottish AI Biotech Recruits Another Pharma Partner in €37M Deal

After Sanofi recruited Exscientia in a €250M deal last May, GSK has taken an interest in the startup and invested in a collaboration of its own. Artificial intelligence has been carving out a niche for itself in biotech, and Exscientia is fast establishing itself as a key player in the field. In May, the company signed a […]

July 3, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 15 Jun 2017

UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech

The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and Google’s Verily to invest in late-stage drug development. After the former life science branch of famous Index Ventures went solo in 2016 and became Medicxi, the VC was able to raise a huge sum of €210M in its first round to support early-stage, single-asset […]

June 15, 2017 - 3 minutesmins - By Melanie De Almeida

Immunocore GSK Immuno oncology collaboration

News and Trends 8 May 2017

Immunocore Boosts its Collaboration with GSK with new Lead Compound

Immunocore has singled out a new lead candidate in its immuno-oncology discovery program with GSK, triggering an undisclosed milestone payment to Immunocore. Based in Oxford, Immunocore is one of the hottest biotechs in the immuno-oncology space, which was able to raise one of the largest European private funding rounds ever (€300M) and is backed by […]

May 8, 2017 - 2 minutesmins - By Melanie De Almeida

Resources

Categories

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

GSK

Why Making the Jump from Pharma to Biotech Can be a Life Changing Experience

EU Approves Two-Drug Pill as First-Line Treatment for HIV

Update: Two-Drug HIV Treatment Effective for up to Three Years

Oxford Biotech Launches with €26M to Target ‘Immunometabolism’

Moving from Big Pharma to Biotech – Insights from Two Biotech CEOs

GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment

Update: GSK’s Shingles Vaccines Impresses FDA Panel who Push for its Approval

Once-a-Day Inhaler Approved for Treatment of Deadly Lung Disease in the US

The 10 Most Innovative HIV Treatments to Defeat AIDS

Scottish AI Biotech Recruits Another Pharma Partner in €37M Deal

UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech

Immunocore Boosts its Collaboration with GSK with new Lead Compound

Subscribe to our newsletter to get the latest biotech news!

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!